Skip to main content

Day: October 9, 2024

Lucent, Inc., a Wholly-Owned Subsidiary of Tipmefast, Inc., Announces Acquisition to Further its Technology Expansion

Santa Ana, CA., Oct. 09, 2024 (GLOBE NEWSWIRE) — Tipmefast, Inc. (OTC: TMEF) today announced that Lucent, Inc. (“Lucent” or the “Company”), its wholly owned subsidiary, continues to expand its role as a leader in the synergy between AI and energy space with a new acquisition in the AI sector. Lucent is developing multiple Artificial Intelligence Platforms from applications developed by Lucent’s working relationship with The National Applied Research Laboratories, Taiwan (ROC), one of the world leaders in AI. Enhancing our model by acquiring key APIs (application programming interfaces) developed by Taiwan National Laboratories enables collaboration with our technology partners.  Steven Arenal, Chairman of Lucent, Inc., said of the recent acquisition, “With an aggressive business model to capitalize on this burgeoning industry,...

Continue reading

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

DOYLESTOWN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has engaged Philippe Pultar, MD as its senior medical advisor to support Aprea with developing and advancing APR-1051, Aprea’s potential best in class WEE1 inhibitor. Dr. Pultar is a seasoned pharmaceutical executive with extensive experience in oncology, including the development of a WEE1 inhibitor (azenosertib) from early to late-stage clinical development. Dr. Pultar has vast experience in clinical development within both large and early-stage pharmaceutical companies. Engaging Dr. Pultar aligns with Aprea’s commitment to provide its WEE1 inhibitor program with all the necessary resources,...

Continue reading

Form 8.3 – [ECKOH PLC – 08 10 2024] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ECKOH PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Poni Insurtech and Global Care Launch Health Insurance Comparison Platform in Vietnam

HO CHI MINH CITY, Vietnam, Oct. 09, 2024 (GLOBE NEWSWIRE) — Poni Insurtech Pte. Ltd. (“Poni Insurtech” or the “Company”), the international arm of Asia’s leading insurance technology platform, Huize Holdings (NASDAQ: HUIZ), today announced that its Vietnam subsidiary, Global Care Consulting Joint Stock Company (“Global Care”), has unveiled its new health insurance comparison platform, “GlobalCare.vn” (https://globalcare.vn). The platform aims to offer Vietnamese consumers an improved, transparent, and user-friendly insurance shopping experience, effectively positioning itself as a one-stop “insurance supermarket.” Mr. Ron Tam, CEO of Poni Insurtech, commented, “We are thrilled to announce our entry into Vietnam in collaboration with founder Niem and her experienced team, following our successful acquisition of Global Care and marking...

Continue reading

Form 8.3 – [KEYWORDS STUDIOS PLC] – 08 10 2024 – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree KEYWORDS STUDIOS PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

Continue reading

Blue Foundry Bancorp Schedules Third Quarter 2024 Earnings Conference Call

RUTHERFORD, N.J., Oct. 09, 2024 (GLOBE NEWSWIRE) — Blue Foundry Bancorp (NASDAQ: BLFY) (the “Company”), the holding company for Blue Foundry Bank, announced that on the morning of Wednesday, October 23, 2024 it will release financial results for the quarter ended September 30, 2024. A copy of the earnings release will be available on the Company’s website, https://ir.bluefoundrybank.com/, in the “News” section and on the SEC’s website, https://www.sec.gov/. Representatives of the Company will hold a conference call for investors and analysts on Wednesday, October 23, 2024 at 11:00AM (ET) to discuss the Third Quarter 2024 Earnings. Blue Foundry Bancorp will address live questions from analysts. The conference call will be recorded and will be available on the Company’s website for one month. We encourage participants to pre-register...

Continue reading

Firan Technology Group Corporation (“FTG”) Announces Third Quarter 2024 Financial Results

TORONTO, Oct. 09, 2024 (GLOBE NEWSWIRE) — Firan Technology Group Corporation (TSX: FTG) today announced financial results for the third quarter of 2024.Third quarter bookings of $45.9M were up 29% over Q3 2023. Third quarter revenues of $43.1M were up 18% over Q3 2023. FTG achieved Adjusted EBITDA in Q3 2024 of $7.2M, which was up 45% over Q3 2023. FTG achieved Net Earnings in Q3 2024 of $2.8M, which was up 109% over Q3 2023.Business Highlights In Q3 2024, FTG once again had strong bookings because of increasing demand from all segments of the Aerospace and Defence market. This, combined with strong operating performance and continued progress in integrating last year’s acquisitions, resulted in the Corporation achieving its best-ever quarterly financial results for revenue, Adjusted EBITDA and Adjusted Net Earnings, and also...

Continue reading

Woodbridge International Closes Sale of Bristol Machine Company to Industrial Threaded Products

NEW HAVEN, Conn., Oct. 09, 2024 (GLOBE NEWSWIRE) — Woodbridge International, a global mergers and acquisitions firm, is pleased to announce the acquisition of its client, Bristol Machine Company by Industrial Threaded Products. Bristol Machine Company headquartered in Ontario, California is the premier distributor and fabricator of fastening systems and industrial products that support various industries including construction, marine, and power (solar, wind energy, pole-line). Industrial Threaded Products (ITP) services the fastener hardware requirements of commercial manufacturers and construction wholesale distributors, nationwide. ITP exists to make customers connections through extensive knowledge and service. Woodbridge International’s ground-breaking approach to marketing a company globally has transformed the way the sell-side...

Continue reading

Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials

Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets Strongest outcomes are generated by the top-ranked AI-Immunology™ vaccine targets, thereby linking AI-vaccine design with real-world evidence This underscores the platform’s unique potential in selecting effective vaccine targets The ongoing generation of relevant clinical data allows for continuous refinement of AI-Immunology™ thereby broadening the commercial potential of the platformCOPENHAGEN, Denmark, October 9, 2024 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has now evidence from three different clinical trials validating the vaccine target predictions of...

Continue reading

Smith+Nephew partners with JointVue™ for Ultrasound preoperative planning in robotics-assisted surgery

Patented technology further personalizes total knee arthroplasty for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed a co-marketing agreement with JointVue for its patented OrthoSonic™ 3D Surgery Planning Technology – the only ultrasound device currently on the market to deliver 3D preoperative planning. JointVue’s technology allows surgeons using Smith+Nephew’s CORI◊ Surgical System for robotic-assisted knee arthroplasty to create a personalized surgical plan, which may provide opportunities to improve patient satisfaction and operating room efficiency. Pre-operative surgical planning provides the surgeon with information about the patient’s anatomy to help the surgeon determine the preferred implants before the surgery begins. This foresight helps...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.